Eric Nudleman
Ophthalmology · San Diego, CANPI 1154582575
Payments from drug & device makers
Across 241 payments — averaging $3118.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$303K
- Alcon$141K
- Genentech USA, Inc.$114K
- Regeneron$92K
- Boehringer Ingelheim International GmbH$27K
- AbbVie$26K
- plus $49K from 15 others
Across 22 payments — averaging $972.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$21K
What the payments were for
- Consulting fees$211,17062%
- Speaking & faculty fees$87,44025%
- Travel & lodging$37,45211%
- Food & beverage$6,9842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $302,883 |
| Alcon | 70 | $141,361 |
| Genentech USA, Inc. | 78 | $113,817 |
| Regeneron | 28 | $92,072 |
| Boehringer Ingelheim International GmbH | 7 | $26,545 |
| AbbVie(2 entities) | 19 | $25,783 |
| Alcon Research LLC | 8 | $21,725 |
| Genentech, Inc. | 5 | $10,990 |
| Spark Therapeutics, Inc. | 4 | $7,054 |
| F. Hoffmann-la Roche AG | 1 | $5,880 |
| Eyepoint US, Inc. | 2 | $1,735 |
| Biocryst Pharmaceuticals, Inc. | 1 | $966 |
| Regeneron Healthcare Solutions, Inc. | 2 | $172 |
| Bausch & Lomb Americas Inc. | 1 | $140 |
| Apellis Pharmaceuticals, Inc. | 1 | $122 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Ocular Therapeutix, Inc. | 1 | $66 |
| Oculus Surgical Inc. | 1 | $50 |
| Alimera Sciences, Inc. | 1 | $48 |
| Amgen | 2 | $48 |
| Astellas Pharma US Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$751,547 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 25 | $890 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $239 |
| Latanoprost | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Diego
- William FreemanSan Diego$997K
- Robert WeinrebSan Diego$660K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.